Based on the mechanism of each component, the patients most likely to benefit from exploring KLOW with their physician are those who: Are actively on a GLP-1 receptor agonist (semaglutide, tirzepatide, retatrutide) and losing weight at a rate of 12+ lb/week Are experiencing visible skin laxity, facial volume loss, or skin texture changes as weight declines Have significant GI side effects (nausea, diarrhoea, mucosal discomfort) during dose escalation Carry known markers of systemic inflammation elevated hsCRP, elevated fasting insulin, or other metabolic biomarkers that have been flagged in prior lab work Are in their 40s or older, where baseline collagen decline makes the gap between demand and capacity most acute Have a history of inflammatory bowel conditions, slow wound healing, or joint/soft tissue injuries that have not fully resolved KLOW is less likely to be the primary tool for patients who are early in GLP-1 therapy, losing weight slowly, have no skin or GI symptoms, and carry no background inflammatory burden
MLP Chicago Week 8 Event home page League Standings and Team/Player Stats MLP 2026 Schedule along with Rosters for the 20 Premier League Teams Transaction Recap & Player News We covered the final trade deadline and final waiver period moves, with in-depth analysis of their impacts, in a separate post late last week
If medication isn't right for you at this time, there are potentially safer paths to weight loss
If you did not build sustainable eating patterns during your time on GLP-1such as portion control, choosing whole foods, or managing stress eatingyour brain may default to old eating habits
However, safety is always our priority
